These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35711029)

  • 1. Dopamine D3 Receptor in Parkinson Disease: A Prognosis Biomarker and an Intervention Target.
    Xu J
    Curr Top Behav Neurosci; 2023; 60():89-107. PubMed ID: 35711029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?
    Yang P; Perlmutter JS; Benzinger TLS; Morris JC; Xu J
    Ageing Res Rev; 2020 Jan; 57():100994. PubMed ID: 31765822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine D1 + D3 receptor density may correlate with parkinson disease clinical features.
    Yang P; Knight WC; Li H; Guo Y; Perlmutter JS; Benzinger TLS; Morris JC; Xu J
    Ann Clin Transl Neurol; 2021 Jan; 8(1):224-237. PubMed ID: 33348472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.
    Carnicella S; Drui G; Boulet S; Carcenac C; Favier M; Duran T; Savasta M
    Transl Psychiatry; 2014 Jun; 4(6):e401. PubMed ID: 24937095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat.
    Lanza K; Chemakin K; Lefkowitz S; Saito C; Chambers N; Bishop C
    Psychopharmacology (Berl); 2020 Jan; 237(1):155-165. PubMed ID: 31435690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.
    Solís O; Garcia-Montes JR; González-Granillo A; Xu M; Moratalla R
    Cereb Cortex; 2017 Jan; 27(1):435-446. PubMed ID: 26483399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The D3 dopamine receptor: From structural interactions to function.
    Fiorentini C; Savoia P; Bono F; Tallarico P; Missale C
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1462-9. PubMed ID: 25532864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia.
    Lanza K; Centner A; Coyle M; Del Priore I; Manfredsson FP; Bishop C
    Exp Neurol; 2021 Feb; 336():113534. PubMed ID: 33249031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.
    Chagraoui A; Di Giovanni G; De Deurwaerdère P
    Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons.
    Bono F; Savoia P; Guglielmi A; Gennarelli M; Piovani G; Sigala S; Leo D; Espinoza S; Gainetdinov RR; Devoto P; Spano P; Missale C; Fiorentini C
    Mol Neurobiol; 2018 Feb; 55(2):1054-1067. PubMed ID: 28092083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.
    Fanni S; Scheggi S; Rossi F; Tronci E; Traccis F; Stancampiano R; De Montis MG; Devoto P; Gambarana C; Bortolato M; Frau R; Carta M
    Neurobiol Dis; 2019 Jan; 121():120-130. PubMed ID: 30261284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
    Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T
    Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.
    Fuxe K; Guidolin D; Agnati LF; Borroto-Escuela DO
    Expert Opin Ther Targets; 2015 Mar; 19(3):377-98. PubMed ID: 25486101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological targeting of G protein-coupled receptor heteromers.
    Moreno E; Casajuana-Martin N; Coyle M; Campos BC; Galaj E; Del Torrent CL; Seyedian A; Rea W; Cai NS; Bonifazi A; Florán B; Xi ZX; Guitart X; Casadó V; Newman AH; Bishop C; Pardo L; Ferré S
    Pharmacol Res; 2022 Nov; 185():106476. PubMed ID: 36182040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral and cellular dopamine D
    Lanza K; Meadows SM; Chambers NE; Nuss E; Deak MM; Ferré S; Bishop C
    Neuropharmacology; 2018 Aug; 138():304-314. PubMed ID: 29936243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer.
    Guitart X; Navarro G; Moreno E; Yano H; Cai NS; Sánchez-Soto M; Kumar-Barodia S; Naidu YT; Mallol J; Cortés A; Lluís C; Canela EI; Casadó V; McCormick PJ; Ferré S
    Mol Pharmacol; 2014 Oct; 86(4):417-29. PubMed ID: 25097189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Dopamine D3 Receptor Heterodimers: Focus on Dopamine D3 and D1 Receptor-Receptor Interaction and Striatal Function.
    Bono F; Mutti V; Tomasoni Z; Sbrini G; Missale C; Fiorentini C
    Curr Top Behav Neurosci; 2023; 60():47-72. PubMed ID: 35505059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection.
    Bono F; Mutti V; Fiorentini C; Missale C
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32659920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptors: homomeric and heteromeric complexes in L-DOPA-induced dyskinesia.
    Solís O; Moratalla R
    J Neural Transm (Vienna); 2018 Aug; 125(8):1187-1194. PubMed ID: 29417335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.